Heparin sodium salt

Inquiry

Cat Number

API0233618

CAS Number

9041-08-1

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

9041-08-1

Synonyms

Nadroparin Sodium, sodium;2-[3,5-bis(2-hydroxyethyl)-1,3,5-triazinan-1-yl]ethanolate

Molecular Formula

C9H20N3NaO3

Molecular Weight

241.26

Smiles

C1N(CN(CN1CCO)CC[O-])CCO.[Na+]

General Description

Heparin sodium is a naturally occurring mucopolysaccharide anticoagulant derived from porcine intestinal mucosa. Initially FDA-approved in 1939, it is available as a sterile injectable solution for intravenous or deep subcutaneous administration.

Mechanism of Action

Heparin exerts its anticoagulant effect by binding reversibly to antithrombin III (ATIII), significantly accelerating the rate at which ATIII neutralizes thrombin (factor IIa) and activated factor X (Xa), along with other coagulation factors including IX, XI, and XII.

Application

Heparin sodium is indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism, prevention of postoperative deep venous thrombosis in patients undergoing major surgery, and management of thromboembolic complications associated with atrial fibrillation. Additional indications include treatment of disseminated intravascular coagulation, prevention of clotting in arterial and cardiac surgery, and use as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures.

Dixon B, et al. randomized 252 mechanically ventilated patients with or at risk of ARDS to receive nebulized heparin or placebo every 6 hours while ventilated. The primary outcome—physical function score at day 60 among survivors—did not differ significantly between groups. However, exploratory secondary outcomes showed that heparin reduced progression to ARDS among at-risk patients (15% vs. 30%; HR 0.46), attenuated deterioration in lung injury score, and resulted in a higher proportion of day-60 survivors being at home (87% vs. 73%; OR 2.45). Day 60 mortality and serious adverse events were similar between groups.

Fig. 1 Development of ARDS by treatment group Cumulative incidence curves for the development of ARDS by day 5. (Dixon B, et al., 2021)

References

Dixon B, et al. Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(4):360-372.

Does Heparin sodium salt require refrigerated storage to maintain its biological activity?

Yes, it should be stored at 2-8°C. As a biological polysaccharide, it is susceptible to degradation at elevated temperatures, which can reduce its anticoagulant activity.

Is Heparin sodium salt sensitive to freezing temperatures?

Freezing should be avoided, as it can cause structural changes and loss of potency. Consistent refrigerated storage without fluctuation is recommended.

What is the recommended humidity level for storing Heparin sodium salt?

It is hygroscopic and should be stored in a low-humidity environment (below 50% RH) in tightly sealed containers to prevent moisture absorption and microbial growth.

How is the potency of Heparin sodium salt verified using biological assays?

We use both USP chromogenic and clotting assays to measure anticoagulant activity, ensuring each batch meets specified potency units per milligram.